Literature DB >> 12484710

Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism.

Paolo Prandoni1, Anthonie W A Lensing, Martin H Prins, Enrico Bernardi, Antonio Marchiori, Paola Bagatella, Michela Frulla, Laura Mosena, Daniela Tormene, Andrea Piccioli, Paolo Simioni, Antonio Girolami.   

Abstract

BACKGROUND: The optimum duration of anticoagulant therapy after an episode of deep venous thrombosis (DVT) is controversial. Contributing to the controversy is uncertainty about whether residual venous thrombosis, as assessed by repeated ultrasonography over time, increases the risk for recurrent thromboembolism.
OBJECTIVE: To determine the risk for recurrent thromboembolism in patients who have persistent residual thrombosis compared with patients who have early vein recanalization.
DESIGN: Prospective cohort study.
SETTING: A university hospital in Padua, Italy. PATIENTS: 313 consecutive symptomatic outpatients with proximal DVT who received conventional short-term anticoagulation. MEASUREMENTS: Ultrasonographic assessment of the common femoral and popliteal veins was performed 3 months after acute DVT in all patients and at 6, 12, 24, and 36 months in patients found to have residual venous thrombosis. Veins were considered recanalized if they were 2.0 mm or less in diameter on a single test or 3.0 mm or less in diameter on two consecutive tests. Recurrent thromboembolism was assessed during a 6-year period.
RESULTS: The cumulative incidence of normal results on ultrasonography was 38.8% at 6 months, 58.1% at 12 months, 69.3% at 24 months, and 73.8% at 36 months. Of 58 recurrent episodes, 41 occurred while the patient had residual thrombosis. The hazard ratio for recurrent thromboembolism was 2.4 (95% CI, 1.3 to 4.4; P = 0.004) for patients with persistent residual thrombosis versus those with early vein recanalization.
CONCLUSIONS: Residual venous thrombosis is an important risk factor for recurrent thromboembolism. Ultrasonographic assessment of residual venous thrombosis may help clinicians modify the duration of anticoagulation in patients with DVT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12484710     DOI: 10.7326/0003-4819-137-12-200212170-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  73 in total

1.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

2.  Multidetector computed tomography venography: optimum dose of contrast material.

Authors:  Yoshiro Hori; Norihiko Yoshimura; Yosuke Horii; Toru Takano
Journal:  Jpn J Radiol       Date:  2010-06-30       Impact factor: 2.374

Review 3.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

Review 4.  Predicting the risk of recurrent venous thromboembolism (VTE).

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

5.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 6.  The epidemiology of venous thromboembolism in the community.

Authors:  John A Heit
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03       Impact factor: 8.311

Review 7.  The postthrombotic syndrome.

Authors:  Raffaele Pesavento; Sabina Villalta; Paolo Prandoni
Journal:  Intern Emerg Med       Date:  2009-12-10       Impact factor: 3.397

8.  Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial.

Authors:  Igor A Suchkov; Javier Martinez-Gonzalez; Sebastian M Schellong; Toni Garbade; Michela Falciani
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 9.  [Therapy and secondary prevention of venous thromboembolism with vitamin K antagonists].

Authors:  R M Bauersachs
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

10.  Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis.

Authors:  T Enden; S Resch; C White; H S Wik; N E Kløw; P M Sandset
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.